



## Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

February 8, 2022

SAN DIEGO and SUZHOU, China, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that members of the company's management will participate in one-on-one investor meetings and provide a corporate update at the SVB Leerink 11<sup>th</sup> Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.

Details on the presentation include:

### SVB Leerink 11<sup>th</sup> Annual Global Healthcare Conference

Presentation Date: Thursday, February 17<sup>th</sup>, 2022

Time: 11:20 a.m. ET

A webcast of the presentation will be accessible in the [investors](#) section of the company's website at <https://www.adagene.com> for at least 30 days.

### About Adagene

Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody®, and POWERbody™ technologies, Adagene's highly differentiated pipeline features novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.

For more information, please visit: <https://investor.adagene.com>. Follow Adagene on [WeChat](#), [LinkedIn](#) and [Twitter](#).

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

### Internal Contact:

Ami Knoefler

Adagene

650-739-9952

[ir@adagene.com](mailto:ir@adagene.com)

### External Contact:

Bruce Mackle

LifeSci Advisors

646-889-1200

[bmackle@lifesciadvisors.com](mailto:bmackle@lifesciadvisors.com)



Source: Adagene, Inc.